The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients
暂无分享,去创建一个
Jian Zhang | Xinzhu Liu | Jihui Chen | Lixia Li | Shuhong Bu | Xiaohui Huang | Xiaoxiao Chen | Jia Zhou | Xiaowen Guo
[1] A. Shorr,et al. Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?-No. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] X. Weng,et al. Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation , 2021, European journal of hospital pharmacy : science and practice.
[3] J. Qu,et al. Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Lykkesfeldt,et al. BCPT policy for experimental and clinical studies , 2020, Basic & clinical pharmacology & toxicology.
[5] Qiaochuan Li,et al. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children , 2020, Journal of clinical pharmacy and therapeutics.
[6] Yao Liu,et al. Dynamic Changes of Staphylococcus aureus Susceptibility to Vancomycin, Teicoplanin, and Linezolid in a Central Teaching Hospital in Shanghai, China, 2008–2018 , 2020, Frontiers in Microbiology.
[7] D. Levine,et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] Peninnah Oberdorfer,et al. Correlation of the vancomycin 24-hour area under the concentration-time curve (AUC24) and trough serum concentration in children with severe infection: A clinical pharmacokinetic study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[9] N. Curtis,et al. Vancomycin is commonly under‐dosed in critically ill children and neonates , 2019, British journal of clinical pharmacology.
[10] S. D. de Wildt,et al. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature , 2019, Archives of Disease in Childhood.
[11] K. Sridharan,et al. Clinical Pharmacokinetics of Vancomycin in Critically Ill Children , 2019, European Journal of Drug Metabolism and Pharmacokinetics.
[12] M. Holubar,et al. Conversion from Vancomycin Trough Concentration–Guided Dosing to Area Under the Curve–Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center , 2019, Pharmacotherapy.
[13] A. Cook,et al. Augmented Renal Clearance , 2019, Pharmacotherapy.
[14] Eric Chang,et al. Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients , 2018, Pharmacotherapy.
[15] Chao Chen,et al. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants , 2018, European Journal of Clinical Pharmacology.
[16] A. Isla,et al. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review , 2018, Clinical Pharmacokinetics.
[17] M. H. Ensom,et al. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review , 2018, Pediatric Drugs.
[18] W. Lu,et al. Population pharmacokinetics of vancomycin in Chinese pediatric patients . , 2017, International journal of clinical pharmacology and therapeutics.
[19] V. Stove,et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? , 2016, The Journal of antimicrobial chemotherapy.
[20] A. Yu,et al. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[21] P. Gao,et al. Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function , 2016, Journal of clinical pharmacology.
[22] J. Pachón,et al. Optimizing the Clinical Use of Vancomycin , 2016, Antimicrobial Agents and Chemotherapy.
[23] Yan Liu,et al. Retrospective Analysis of Vancomycin Nephrotoxicity in Elderly Chinese Patients , 2015, Pharmacology.
[24] M. Neely,et al. Innovative approaches to optimizing the delivery of vancomycin in individual patients. , 2014, Advanced drug delivery reviews.
[25] Tsz-Yin So,et al. An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents , 2011, International journal of pediatrics.
[26] J. Roberts,et al. Implications of augmented renal clearance in critically ill patients , 2011, Nature Reviews Nephrology.
[27] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] D. Levine,et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Susan L Furth,et al. New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.
[30] R. Sawchuk,et al. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients , 1976, Journal of Pharmacokinetics and Biopharmaceutics.
[31] B. Kasiske,et al. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword , 2013 .
[32] D. Paterson,et al. Augmented Renal Clearance , 2010, Clinical pharmacokinetics.